Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron

Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). 

LEARN MORE

women-sleeping

Latest News

The latest posts and articles

Urovant Sciences Enters into Flexible…

February 22, 2019 at 5:20 PM EST IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Feb. 22, 2019–…

Urovant Sciences Reports Financial Results…

February 13, 2019 at 4:05 PM EST BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Feb. 13, 2019–…

Copyright 2018 © All Rights Reserved